PMID- 27659698
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20170206
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 128
IP  - 8
DP  - 2016 Nov
TI  - Lorcaserin treatment allows for decreased number needed to treat for weight and 
      glycemic parameters in week 12 responders with >/=5% weight loss.
PG  - 740-746
AB  - OBJECTIVES: Lorcaserin is a serotonin 2C receptor agonist approved for chronic 
      weight management. This analysis explores the number of patients needed to be 
      treated (NNT) with lorcaserin for one more patient to achieve weight loss and 
      glycemic goals. METHODS: This is a post hoc analysis of three Phase 3 studies in 
      adults with and without type 2 diabetes mellitus (T2DM) treated with lorcaserin 
      10 mg BID or placebo. NNT is reported for patients achieving >/=5% or >/=10% weight 
      loss, achievement of either HbA1c <5.7% or FPG <100 mg/dL in patients with 
      prediabetes, and reduction of HbA1c to <7% in patients with T2DM at Week 52. 
      RESULTS: In the modified intention-to-treat (MITT) population, NNTs for >/=5% and 
      >/=10% weight loss were 3.6 and 6.2 (without T2DM) and 4.3 and 7.5 (with T2DM); in 
      Week 12 responders (>/=5% weight loss at Week 12), NNTs were 1.7 and 2.6 (without 
      T2DM) and 1.9 and 3.2 (with T2DM). In patients with prediabetes, NNTs to achieve 
      HbA1c <5.7% were 9.9 (MITT) and 5.2 (Week 12 responders). In patients with T2DM, 
      NNTs to achieve HbA1c <7% were 4.2 (MITT) and 2.3 (Week 12 responders). 
      CONCLUSION: In addition to weight management, lorcaserin improved glycemic 
      control in patients with prediabetes and facilitated targeted HbA1c reduction in 
      patients with T2DM, especially for those who achieved >/=5% weight loss by Week 12. 
      Assessment of treatment response at Week 12 is a valuable tool to achieve 
      efficient use of healthcare resources. CLINICAL TRIAL REGISTRATION: 
      www.clinicaltrials.gov identifiers are NCT00395135, NCT00603291, and NCT00603902.
FAU - Handelsman, Yehuda
AU  - Handelsman Y
AD  - a Metabolic Institute of America , Tarzana , CA , USA.
FAU - Fain, Randi
AU  - Fain R
AD  - b Department of Medical and Scientific Affairs , Formerly of Eisai Inc. , 
      Woodcliff Lake , NJ , USA.
FAU - Wang, Zhixiao
AU  - Wang Z
AD  - c Department of Health Economics & Outcomes Research, Eisai Inc. , Woodcliff Lake 
      , NJ , USA.
FAU - Li, Xuan
AU  - Li X
AD  - c Department of Health Economics & Outcomes Research, Eisai Inc. , Woodcliff Lake 
      , NJ , USA.
FAU - Fujioka, Ken
AU  - Fujioka K
AD  - d Department of Diabetes and Endocrinology , Scripps Clinic , La Jolla , CA , 
      USA.
FAU - Shanahan, William
AU  - Shanahan W
AD  - e Department of Clinical Development , Formerly of Arena Pharmaceuticals, Inc. , 
      San Diego , CA , USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00395135
SI  - ClinicalTrials.gov/NCT00603291
SI  - ClinicalTrials.gov/NCT00603902
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20161019
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Benzazepines)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Serotonin 5-HT2 Receptor Agonists)
RN  - 637E494O0Z (lorcaserin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Benzazepines/administration & dosage/*therapeutic use
MH  - Blood Glucose/drug effects
MH  - Body Mass Index
MH  - Body Weight/drug effects
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Exercise
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Obesity/*drug therapy
MH  - Prediabetic State/*drug therapy
MH  - Serotonin 5-HT2 Receptor Agonists/administration & dosage/*therapeutic use
MH  - Weight Loss/drug effects
MH  - Young Adult
OTO - NOTNLM
OT  - Lorcaserin
OT  - glycemic benefits
OT  - number needed to treat
OT  - weight management
EDAT- 2016/09/24 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/09/24 06:00
PHST- 2016/09/24 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
PHST- 2016/09/24 06:00 [entrez]
AID - 10.1080/00325481.2016.1240591 [doi]
PST - ppublish
SO  - Postgrad Med. 2016 Nov;128(8):740-746. doi: 10.1080/00325481.2016.1240591. Epub 
      2016 Oct 19.